Drug Trial Radar · NCT07071532
A Study to Assess Adverse Events and How Oral ABBV-932 Moves Through the Body When Given With Oral Itraconazole in Adult Participants With Bipolar Disorder
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Aug 20, 2026
Primary completion
Feb 2027
Study completion Feb 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jul 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the adverse events and how oral ABBV-932 moves through the body when given with oral Itraconazole in adult participants with bipolar disorder.
Conditions
- Bipolar Disorder
Interventions
ABBV-932Drug
Oral Capsule
ItraconazoleDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
- Time to Cmax (Tmax) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
- Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
- Apparent terminal phase elimination rate constant (β) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
- Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
- Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932 and active metabolites DCAR and DDCARTime frame: Up to approximately 29 days
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 61 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
CenExel Collaborative Neuroscience Research /ID# 282784
Los Alamitos, California · Recruiting
Acpru /Id# 276951
Grayslake, Illinois · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.